In this study, adults with Chronic Primary Immune Thrombocytopenia (ITP) have a low platelet count because their immune system destroys these cells. Platelets help stop bleeding, so having fewer can make it easier to bruise or bleed. The study will see if a new medicine called mezagitamab, when injected under the skin, can keep platelet levels stable compared to a placebo, which looks like medicine but has no active ingredients.
Participants will receive mezagitamab for up to 6 months and need to visit the clinic several times. If the treatment works and they are eligible, they might continue in another study to keep receiving the medicine.
- Participants must have had ITP for at least 12 months and tried other treatments.
- Participants should know that the study lasts up to 6 months with several clinic visits.
- They must not have certain conditions, like other infections or recent cancer history.
It's important to discuss with a doctor to see if joining the study is a good choice.
How understandable was the trial content above?
Hard to understand
Easy to understand